ArticleScientific reports2015
The aglycone of ginsenoside Rg3 enables glucagon-like peptide-1 secretion in enteroendocrine cells and alleviates hyperglycemia in type 2 diabetic mice.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 66 citations in OpenAlex.
- Dual Activation of GLP-1 and AMPK Pathways by a Multi-Botanical Formulation Improves Obesity and Metabolic Dysfunction in Experimental Models.Nutrients · 2026Article
- Ginsenosides in Modern Pharmaceutics: Mechanisms, Applications, Challenges, and Perspectives.Biomolecules · 2026Review
- Emerging Breakthroughs in Nano-Ginseng Innovations and Their Therapeutic Implications in Type 2 Diabetes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Dissecting the anti-obesity components of ginseng: How ginseng polysaccharides and ginsenosides target gut microbiota to suppress high-fat diet-induced obesity.Journal of advanced research · 2025Article
- Genome-wide identification and integrated analysis of the WNK kinase gene family and expression analysis of PgWNK genes under methyl jasmonate treatment in Panax ginseng.BMC plant biology · 2025Article
- Abilities of Rare Sugar Members to Release Glucagon-like Peptide-1 and Suppress Food Intake in Mice.Nutrients · 2025Article
- GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation.Diabetology & metabolic syndrome · 2025Review
- Ginsenoside in the treatment of type 2 diabetes and its complications: a promising traditional chinese medicine.Frontiers in pharmacology · 2025Review
- Transformation from passive health to proactive prevention: research progress on glucose-lowering components and its mechanism of food and medicine homology resources.Frontiers in nutrition · 2025Review
- Article
- Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Ginsenosides for the treatment of insulin resistance and diabetes: Therapeutic perspectives and mechanistic insights.Journal of ginseng research · 2024Review
- Timosaponin A3 Induces Anti-Obesity and Anti-Diabetic Effects In Vitro and In Vivo.International journal of molecular sciences · 2024Article
- Research progress in the treatment of an immune system disease-type 1 diabetes-by regulating the intestinal flora with Chinese medicine and food homologous drugs.Bioscience of microbiota, food and health · 2024Review
- Protopanaxadiol ameliorates palmitate-induced lipotoxicity and pancreatic β-cell dysfunction in INS-1 cells.Journal of ginseng research · 2023Article
- Isosinensetin Stimulates Glucagon-like Peptide-1 Secretion via Activation of hTAS2R50 and the GInternational journal of molecular sciences · 2023Article
- Some Common Medicinal Plants with Antidiabetic Activity, Known and Available in Europe (A Mini-Review).Pharmaceuticals (Basel, Switzerland) · 2022Review
- Effect of the Gintonin-Enriched Fraction on Glucagon-Like-Protein-1 Release.Molecules (Basel, Switzerland) · 2021Article
- The effects of ginseng on the metabolic syndrome: An updated review.Food science & nutrition · 2021Review
- Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginsenosides can be classified on the basis of the skeleton of their aglycones. Here, we hypothesized that the sugar moieties attached to the dammarane backbone enable binding of the ginsenosides to the sweet taste receptor, eliciting glucagon-like peptide-1 (GLP-1) secretion in the enteroendocrine L cells. Using the human enteroendocrine NCI-H716 cells, we demonstrated that 15 ginsenosides stimulate GLP-1 secretion according to the position of their sugar moieties. Through a pharmacological approach and RNA interference technique to inhibit the cellular signal cascade and using the Gαgust(-/-) mice, we elucidated that GLP-1 secreting effect of Rg3 mediated by the sweet taste receptor mediated the signaling pathway. Rg3, a ginsenoside metabolite that transformed the structure through a steaming process, showed the strongest GLP-1 secreting effects in NCI-H716 cells and also showed an anti-hyperglycemic effect on a type 2 diabetic mouse model through increased plasma GLP-1 and plasma insulin levels during an oral glucose tolerance test. Our study reveals a novel mechanism where the sugar moieties of ginsenosides Rg3 stimulates GLP-1 secretion in enteroendocrine L cells through a sweet taste receptor-mediated signal transduction pathway and thus has an anti-hyperglycemic effect on the type 2 diabetic mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.